Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WecA inhibitor (Prokaryotics)
- Development stage
- Preclinical
- Lead developer
- Prokaryotics
- Modality
- Small Molecules
- Administration
- Aerosol
01
Overview
WecA inhibitor (Prokaryotics) is a preclinical-stage small molecule antibiotic candidate developed by Prokaryotics, Inc. It targets the bacterial enzyme WecA (UDP-N-acetylglucosamine--undecaprenyl-phosphate N-acetylglucosaminephosphotransferase), which is essential for the biosynthesis of the bacterial cell envelope. WecA is involved in the initiation of the assembly of various cell wall components, including O-antigen and Enterobacterial Common Antigen (ECA). By inhibiting this enzyme, the drug disrupts bacterial cell wall assembly and integrity, representing a novel approach to treating serious multidrug-resistant (MDR) bacterial infections. The program has received SBIR funding and is currently in the lead optimization or preclinical development phase.
- Other names
- Serine-mediated Paint
02
Targets
WecA (UDP-N-acetylglucosamine 1-phosphate transferase)
Beyond the preview
Go deeper on WecA inhibitor (Prokaryotics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WecA inhibitor (Prokaryotics).